QCM Cayman’s Bionano Genomics BNGO Stock Holding History

QCM Cayman’s Portfolio BNGO Stock Details BNGO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-18	Closed	-$27K	–	37
2022 Q1	$27K	Sell	18 -12	-40%	-$16.2K	0.12%	83
2021 Q4	$54K	Buy	30 +6	+25%	+$16K	0.33%	60
2021 Q3	$79K	Buy	+24	New	+$83.9K	0.22%	102

Other funds holding BNGO

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Mitsubishi UFJ Asset Management Tokyo, Japan $149B AUM 24.71% 1-Year Est. Return

QCM Cayman's BNGO Position: Q2 2022 in Review

QCM Cayman sold out of Bionano Genomics (BNGO) in Q2 2022, closing a stake of 18 shares — an estimated $27K sold.

QCM Cayman first reported a position in BNGO in Q3 2021 and held it in 3 quarters. The position peaked at $79K in Q3 2021. 143 funds tracked by Wall St. Rank hold BNGO as of Q2 2022.

QCM Cayman reported no remaining Bionano Genomics position as of Q2 2022 after selling out during the quarter.
QCM Cayman sold 18 Bionano Genomics shares in Q2 2022, an estimated $27K.
QCM Cayman first reported a position in Bionano Genomics in Q3 2021 and held it in 3 quarters.
QCM Cayman's Bionano Genomics position peaked at $79K in Q3 2021.
143 funds tracked by Wall St. Rank held Bionano Genomics as of Q2 2022.

Based on QCM Cayman's 13F filing for Q2 2022, filed 27 Jul 2022.